What Ikonisys does

Ikonisys (operating under the ALIKO SCIENTIFIC group brand since 2024) is a publicly traded medical technology company founded in 1999 in New Haven, Connecticut, that develops automated Fluorescence In Situ Hybridization (FISH) systems for cancer diagnostics. Its core platform pairs the Ikoniscope20 and Ikoniscope20max automated fluorescence microscopes with the proprietary Ikonisoft software suite, enabling walk-away, high-throughput identification, analysis, and enumeration of rare cells in biological samples for applications including bladder cancer screening (oncoFISH bladder), HER2 amplification in breast cancer, ALK rearrangements in non-small cell lung cancer, PTEN deletions in prostate cancer, and circulating tumor cell detection. The company serves oncology diagnostic laboratories, hospital pathology departments, and specialty urology and cancer care providers, with named enterprise customers including Quest Diagnostics, Synlab, Genesis Care, and the Michigan Institute of Urology.

The company generates revenue through three primary streams: capital equipment sales of Ikoniscope systems at list prices of USD 160,000 to USD 296,000 per unit, recurring consumable revenue from proprietary FISH probes and reagents, and a pay-per-test model starting at USD 99 per test that bundles hardware, reagents, software, and maintenance. Following the April 2024 acquisition of Italian-based Hospitex International for EUR 4.5 million (plus contingent earnouts), Ikonisys extended its portfolio to include Liquid-Based Cytology systems (CYTOfast, CYTOfast Plus, CYTOfast Biobank, CYTOfast Urine24), creating an integrated workflow from cytological sample preparation through FISH-based genetic analysis. Distribution combines direct enterprise field sales to large diagnostic chains with a worldwide distributor network actively being expanded, particularly across EMEA.

The company operates from offices in New Haven (US headquarters), Paris (European holding company Aliko Scientific SA, listed on Euronext Growth Paris under ticker ALIKO), Milan, and Florence (European Reference Lab). Ikonisys has sold approximately 30 Ikoniscope microscopes cumulatively and reports 300,000+ FISH tests performed on its platform. Leadership includes CEO Mario Crovetto, CSO Michael Kilpatrick, CFO Alessandro Mauri, CDO Alessandro Nosei, and COO Francesco Trisolini, with Mario Mauri as Chairman of the Board. The company holds FDA clearances for multiple diagnostic applications, CE certification for European distribution, and ISO 13485 compliance, and has raised several rounds of private placement capital totaling approximately EUR 3.4 million between 2023 and 2025 alongside the Hospitex acquisition.

Name

Ikonisys

Legal name

Ikonisys Inc.

Website

https://ikonisys.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

51–100 employees

Short description

Ikonisys (ALIKO SCIENTIFIC) develops automated FISH microscopy systems and software for cancer diagnostics, serving oncology laboratories, hospital pathology departments, and large diagnostic chains such as Quest Diagnostics, Synlab, and Genesis Care.

Ownership category

akta.pro rank

Product category

Automated Cancer Diagnostic Systems

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

akta.pro secondary industries

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Automated FISH microscopy
• Cancer diagnostic systems
• Fluorescence in situ hybridization
• Digital pathology platforms
• Liquid-based cytology

Headquarters

HQ city

New Haven

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. FISH Microscopy Hardware Sales: Sale of Ikoniscope20 and Ikoniscope20max automated fluorescence microscopy systems. One-time capital equipment purchase with list prices ranging from $160,000-$296,000 depending on model. Includes initial installation and setup.
2. Pay-per-Test Model: All-inclusive model starting from $99 per test including device, probes, software, setup, and maintenance. Provides predictable per-test pricing eliminating large upfront capital expenditure for laboratories.
3. FISH Reagents and Probes: Consumable revenue from proprietary FISH probes and reagents required for each test. Direct line of FISH probes production mentioned as part of R&D focus.
4. Diagnostic Applications (oncoFISH): FDA-cleared diagnostic applications including oncoFISH bladder, oncoFISH HER2, oncoFISH cervical, oncoFISH PTEN, oncoFISH ALK, and Explorer applications for various cancer types.
5. Professional Services: Integration services for Hospitex acquisition, installation support, and training services for laboratory personnel on FISH system operation.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Ikonisys designs, manufactures, and sells fully-automated fluorescence microscopy systems (Ikoniscope20 and Ikoniscope20max) paired with proprietary Ikonisoft software for cancer diagnostics using Fluorescence In Situ Hybridization (FISH) technology. The platform enables walk-away automated detection of genetic abnormalities in tissue, blood, and cell suspensions for oncology laboratories, and following the 2024 Hospitex acquisition extends into Liquid-Based Cytology sample preparation via the CYTOfast system. The company sells capital equipment, pay-per-test consumables/probes, FDA-cleared diagnostic applications (oncoFISH), and professional integration services to diagnostic laboratories and hospital networks.

Product overview

Ikonisys operates as a platform-plus-modules architecture offering the Ikoniscope automated fluorescence microscopy system as the core hardware platform running proprietary Ikonisoft software. The product portfolio spans three main categories: automated FISH microscopes (Ikoniscope20 and Ikoniscope20max), diagnostic software applications (oncoFISH HER2, bladder, ALK, PTEN, and Explorer applications), and CTC detection capabilities. Following the 2024 acquisition of Hospitex International, the portfolio expanded to include Liquid-Based Cytology products (CYTOfast System, CYTOfast Plus, Biobank, and Urine24). The integrated system enables laboratories to combine morphological data from LBC samples with genetic data from FISH analysis for comprehensive cancer diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Ikoniscope: Automated digital microscope platform for FISH diagnostics
• Ikonisoft
• oncoFISH
• Hospitex
• CYTOfast
• IkoniWAN

Products and services

• Ikoniscope20 Automated FISH Microscope FDA-cleared and CE-marked automated fluorescence microscope for high-productivity FISH diagnostics in oncology laboratories. Capable of scanning and analyzing up to 2,000,000 cells on a single slide with walk-away automation, robotic slide handling, and continuous operation. List price $160,000-$218,000 per unit.
• Ikoniscope20max High-Throughput FISH Microscope High-throughput version of the automated fluorescence microscope with capacity up to 160 slides per instrument, designed for mass productivity in high-volume laboratories. List price $230,000-$296,000 per unit.
• Ikonisoft Software Platform Proprietary software platform that manages robotic components, image acquisition, and cell detection for the Ikoniscope system, enabling true hands-off slide handling for continuous operation and supporting oncoFISH diagnostic applications.
• CYTOfast Plus Liquid-Based Cytology Processor Advanced liquid-phase cytology processor utilizing Nephelometric Smart Technology (NST) for preparing thin-layer cytological samples at 60 slides per hour, integrated with the Ikonisys FISH workflow following the Hospitex acquisition.
• Pay-per-Test Diagnostic Service All-inclusive pay-per-test service starting from $99 per test that bundles the Ikoniscope device, probes, software, setup, and maintenance into a single predictable per-test price, eliminating the upfront capital expenditure of system purchase for laboratories.

Quantifiable outcome

• 65% reduction in labor costs compared to manual workflow
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• UConn HealthcoreStrategic or Co-development PartnerHealthcare division of University of Connecticut encompassing medical school, dental school, and hospital. Scientific partnership for patient care, education, and research collaboration in cancer diagnostics.
• Polytechnic University of MilancoreStrategic or Co-development PartnerAcademic partnership with facilities having advanced equipment and qualified teams dedicated to research and innovation, experimentation, collaboration, and technology transfer activities.
• TomaLab MilanminorStrategic or Co-development PartnerLaboratory specializing in medical diagnostics and development of innovative health technologies. Partnership for advancing diagnostic solutions.
• ImpactLabminorStrategic or Co-development PartnerResearch initiative that evaluates and maximizes the societal and technological impact of scientific and industrial projects.
• University of Oxford (Sir Walter Bodmer's group)coreStrategic or Co-development PartnerInitial validation of Ikoniscope platform for CTC detection and analysis conducted with Sir Walter Bodmer's group. Demonstrated straightforward and rapid procedure for definitive CTC identification.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• MetaSystems: Germany-based specialist manufacturer of automated microscope platforms and software for FISH and chromosome analysis, the closest direct competitor to Ikonisys in automated FISH diagnostics for cytogenetics and oncology.
• BioView: Israeli company developing automated imaging and analysis systems for FISH, circulating tumor cell detection, and cytogenetics — directly comparable technology stack and clinical applications to Ikonisys's Ikoniscope platform.

Broad incumbents

• Leica Biosystems (Danaher): Major pathology and FISH workflow provider within Danaher's diagnostics portfolio, offering the Bond-III staining platform and FISH analysis software used widely in clinical and research pathology labs globally.
• Abbott Molecular: Large diagnostics incumbent providing FISH probes (Vysis product line) and molecular diagnostic instruments for oncology, reproductive health, and infectious disease — overlapping with Ikonisys's oncoFISH and probe business.
• Revvity (formerly PerkinElmer Life Sciences): Diversified life sciences and diagnostics company offering reagents, imaging instruments, and analytical solutions used in genomics, cell biology, and clinical diagnostics — overlapping with Ikonisys's FISH reagents and microscopy hardware.
• Carl Zeiss Microscopy: Global leader in research-grade and clinical microscopy systems. While not a FISH-automation specialist, its microscope platforms and imaging software compete for capital equipment budget within the same pathology laboratory customers.
• Olympus Life Science: Major microscopy and clinical imaging vendor serving pathology and cytogenetics laboratories worldwide with slide scanners and fluorescence microscope systems that overlap Ikonisys's core instrument offering.
• Hamamatsu Photonics: Specialist in photonics and imaging components including high-sensitivity cameras and digital slide scanners used in fluorescence microscopy and pathology — overlapping technology footprint with Ikoniscope imaging hardware.
• NeoGenomics: US oncology-focused clinical laboratory services company performing FISH, NGS, and other molecular oncology testing at scale — overlapping with Ikonisys's customer base and use cases while operating a service rather than instrument business model.
• Hologic: Diversified diagnostics and women's health company with a portfolio that includes cytology (ThinPrep) and molecular diagnostic systems, partially overlapping Ikonisys's cytology-prep workflow after the Hospitex acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ikonisys

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ikonisys